Full Editor
Likes Subject
HORRENDOUS DUMPING Disquisition 12/14/22 5:03 PM
$50,000,000 share offering. This is adding approximately 1/6 make it happen 03/30/22 9:41 AM
lol TrendTrade2016 03/23/22 10:12 AM
Nice analysis TrendTrade2016 03/22/22 12:16 PM
lmao TrendTrade2016 03/21/22 11:59 AM
monster rare drug play TrendTrade2016 03/21/22 11:45 AM
very nice push coming....rare disease drugs are expensive!! TrendTrade2016 03/21/22 11:19 AM
Literally losing over $440,000,000 million a year with make it happen 03/17/22 11:16 AM
Volume is not sustainable imo and did a make it happen 03/17/22 10:33 AM
watch and learn loser TrendTrade2016 03/17/22 10:28 AM
Mid tripple digit negative profitability over 600% NEGATIVE. make it happen 03/17/22 9:43 AM
EIGR monster TrendTrade2016 03/17/22 9:37 AM
massive bio play taking off in pre! TrendTrade2016 03/17/22 9:03 AM
jhpratt@alphavestcapital.com is my email.Please email me insights into eigr. ae kusterer 02/08/21 8:50 PM
Dead though lol Penny chatter 11/23/20 8:57 AM
more NEWS https://ih.advfn.com/stock-market/NASDAQ/eiger-biopharmaceuticals-EIGR TheFinalCD 11/23/20 8:53 AM
Let’s go over $20... Oger 11/22/20 11:01 PM
They say the right things in the conference Penny chatter 11/22/20 10:41 PM
You think this rocks tomorrow penny chatter? Oger 11/22/20 10:37 PM
Think someone will be stated it. I looked Penny chatter 11/22/20 10:35 PM
Who’s the buyer? Oger 11/22/20 10:33 PM
Folks miss the covid implications here and they Penny chatter 11/22/20 6:24 PM
It will sink it the magnitude of this Oger 11/21/20 11:16 AM
I agree as it has 80% institutional ownership Penny chatter 11/21/20 9:15 AM
Over $20 on Monday...... Oger 11/20/20 10:11 PM
They didn't have to halt for this lol Penny chatter 11/20/20 7:45 PM
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment TheFinalCD 11/20/20 7:16 PM
What kind of fda approval don't see interest? Penny chatter 11/20/20 7:12 PM
On it Penny chatter 11/20/20 6:10 PM
HALTED PENDING NEWS 11/20/2020 16:53:30 EIGR Eiger BioPharma NASDAQ TheFinalCD 11/20/20 5:00 PM
EIGR - Lambda is most paradoxical interferon : Fezziwig2008 08/22/20 1:08 PM
A mutual friend we have really likes it. Small MWM 08/18/20 9:10 PM
EIGR is expected to release interim data from Fezziwig2008 08/18/20 8:46 PM
https://seekingalpha.com/instablog/52316800-friar-tuck-esq/5480909-eiger-biophar MWM 08/18/20 3:59 PM
$EIGR what is Cooking? MWM 08/18/20 3:49 PM
EIGR is cooking... MWM 08/10/20 10:02 AM
EIGR ”Although no synthetic IFN-lambda is yet FDA-approved, Fezziwig2008 08/03/20 10:54 AM
On EIGR (Lambda is IFN III) “Treatment with Fezziwig2008 07/29/20 6:14 AM
EIGR “IFN-Lambda4 showed a strong therapeutic effect in Fezziwig2008 07/26/20 4:40 PM
EIGR ”Although no synthetic IFN-lambda is yet FDA-approved, Fezziwig2008 07/22/20 11:22 PM
New EIGR LAMBDA Trial in Canada -Why would Fezziwig2008 07/19/20 11:00 AM
EIGR Antiviral Anti ARDS Mechanism of Action -Derek Fezziwig2008 07/16/20 11:41 AM
EIGR for COVID ARDS -“We conclude that IFN Fezziwig2008 07/16/20 10:30 AM
EIGR Science on IHUB not Twitter. Fezziwig2008 07/15/20 10:26 AM
EIGR Positive Data from Stanford Soon “IFN-? has Fezziwig2008 07/15/20 9:49 AM
EIGR on watch... MWM 06/09/20 9:33 AM
8.4M common shares outstanding xr_biotech_consult 07/31/17 3:35 PM
$49M cash and investments as of March 31, 2017 xr_biotech_consult 07/31/17 3:35 PM
Oppenheimer Reaffirms $34 Target On Eiger Biopharmaceuticals (EIGR), xr_biotech_consult 07/31/17 3:33 PM
Out at $9.60. But way stronger than had chmcnfunds 07/14/17 12:51 PM
Likes Subject

12/14/22 5:03 PM
03/23/22 10:12 AM
03/22/22 12:16 PM
03/21/22 11:59 AM
03/21/22 11:45 AM
make it happen
03/17/22 10:33 AM
03/17/22 10:28 AM
03/17/22 9:37 AM
03/17/22 9:03 AM
Penny chatter
11/23/20 8:57 AM
11/22/20 11:01 PM
Penny chatter
11/22/20 10:41 PM
Penny chatter
11/22/20 10:35 PM
11/22/20 10:33 PM
Penny chatter
11/22/20 6:24 PM
11/21/20 11:16 AM
Penny chatter
11/21/20 9:15 AM
11/20/20 10:11 PM
Penny chatter
11/20/20 7:45 PM
Penny chatter
11/20/20 7:12 PM
Penny chatter
11/20/20 6:10 PM
08/22/20 1:08 PM
08/18/20 8:46 PM
08/18/20 3:49 PM
08/10/20 10:02 AM
07/29/20 6:14 AM
07/19/20 11:00 AM
07/16/20 10:30 AM
07/15/20 10:26 AM
06/09/20 9:33 AM
07/31/17 3:35 PM
07/31/17 3:35 PM
07/14/17 12:51 PM

Eiger BioPharmaceuticals (EIGR)

Posts (Today)
Posts (Total)

Celladon to Merge with Eiger

 Celladon Corporation (Nasdaq:CLDN) and Eiger BioPharmaceuticals, Inc., a privately-held biopharmaceutical company, today announced that they have entered into a definitive merger agreement under which the stockholders of Eiger would become the majority owners of Celladon, and the operations of Celladon and Eiger would be combined. The proposed merger remains subject to certain conditions, including the approval of Celladon stockholders.  If approved, upon closing of the transaction, Celladon will be renamed Eiger BioPharmaceuticals, Inc.
An investor syndicate has committed to invest $39.5 million in the combined company including new investors HBM Healthcare Investments, RA Capital Management, Sabby Management, Sphera Global Healthcare, Perceptive Advisors and Monashee Capital Partners together with existing long-time Eiger stockholders, ViVo Capital and InterWest Partners.  Six million dollars of the financing has already been funded, and the remaining $33.5 million is expected to close contemporaneously with the completion of the proposed merger.  The total cash balance of the combined company upon the closing of the proposed merger and the financing is expected to be greater than $60 million.
The proposed merger will create a clinical-stage company with a diversified development portfolio of product candidates addressing novel targets for four distinct orphan diseases: Hepatitis Delta Virus, bariatric surgery-induced hyperinsulinemic hypoglycemia, pulmonary arterial hypertension, and lymphedema.


Current Share Structure:

Outstanding shares as of October 31, 2015 was 23,916,021

Authorized shares as of October 31, 2015 was 200,000,000



About the Proposed Merger

Existing Eiger stockholders as well as investors in the contemporaneous financing will receive newly issued shares of Celladon common stock in connection with the proposed merger.  Celladon is expected to issue approximately 85.0 million new shares of its common stock to Eiger stockholders and participants in the financing.  On a pro forma basis for the combined company, current Celladon shareholders are expected to own approximately 22%, current Eiger shareholders approximately 45% and the new Eiger investor syndicate approximately 33%, each on a fully-diluted basis.

The transaction has been unanimously approved by the boards of directors of both companies, and a majority of Eiger stockholders have agreed to vote in favor of the transaction. The proposed merger is expected to close in the first half of 2016, subject to the approval of the stockholders of each company as well as regulatory approval and other customary conditions.  The merger agreement contains further details with respect to the proposed merger.

Celladon’s exclusive financial advisor in the transaction is Wedbush PacGrow Healthcare.  Jefferies LLC is acting as lead financial advisor to Eiger and Piper Jaffray is acting as financial advisor.  Pillsbury Winthrop Shaw Pittman LLP served as legal counsel to Celladon and Cooley LLP served as legal counsel to Eiger.


Most Liked Posts
(Last 30 Days)
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Most Liked Posts
(Last 30 Days)
New Post